This presentation will explore the transformative impact of deploying a Manufacturing Execution System (MES) across multiple sites in the biologics division, focusing on the various stages of adoption. As the industry shifts towards newer modalities, such as cell and gene therapy, the complexity of the manufacturing process has increased significantly, heightening the risk of human error in documentation. To address this challenge, CTLT has adopted an innovative approach to digitizing batch records in its Gene Therapy operations using a non-traditional MES solution—Apprentice. This presentation will outline how different sites are navigating their digital transformation journeys at varying speeds and how production priorities can influence the adoption of digital resources. You will learn how to:

• Navigate the complexities of adopting digital solutions in biologics manufacturing across multiple sites with varying resource availability.
• Assess the impact of prioritizing production needs while implementing new technologies, ensuring a smooth transition.
• Drive cultural change within teams to foster successful adoption of new processes and minimize human error in documentation.